Second-Line Status Epilepticus Therapy After ESETT: Does Equivalence Change the Choice
A single patient in benzodiazepine-refractory status epilepticus. ESETT found levetiracetam, fosphenytoin, and valproate roughly equivalent — his own history is what actually decides between them.
R.H., a 61-year-old man with a history of ischemic cardiomyopathy and an ejection fraction of 30% on his most recent echocardiogram, was brought in by his wife after a witnessed convulsive seizure that has continued despite two full 4mg doses of IV lorazepam — the guideline's per-dose ceiling, given and then repeated ten minutes apart — benzodiazepine-refractory status epilepticus by any reasonable definition. He has no prior seizure history; his wife reports he'd complained of a headache and felt “off” for two days beforehand, and initial labs show a sodium of 121, low enough on its own to plausibly explain a first seizure.
ESETT, the largest randomized trial comparing second-line agents for exactly this situation, found levetiracetam, fosphenytoin, and valproate performed roughly equivalently on its primary outcome — seizure cessation and improved consciousness within an hour — a genuinely surprising result to a field that had long assumed real differences existed, and the trial was in fact stopped early for futility in finding one. What ESETT's equivalence finding doesn't erase is that the three drugs remain pharmacologically different in every other respect — their cardiovascular effects, their hepatic burden, their interaction profiles — and R.H.'s own history puts weight on exactly those differences. Fosphenytoin carries a real risk of hypotension and cardiac conduction effects during rapid IV loading, a genuine concern in a patient with an ejection fraction this reduced; valproate carries hepatotoxicity risk and, separately, can itself lower sodium, complicating a picture that already includes a sodium of 121. His sodium is doing double duty in this case, which is worth naming plainly: at 121 it is low enough to be a sufficient cause of a first seizure in a man with no prior seizure history, and it is also the number most constrained in how fast it can be corrected. That makes it simultaneously the likely trigger and a second, parallel management problem running alongside the drug choice rather than downstream of it.
Choosing among three equivalent options
ESETT genuinely found no meaningful difference among levetiracetam, fosphenytoin, and valproate on seizure cessation — stopped early specifically because no signal of difference was emerging. Given that, I'd default to levetiracetam here specifically because of his cardiomyopathy: it has no clinically significant cardiovascular loading effects, unlike fosphenytoin's real hypotension and conduction risk during rapid infusion in a patient with an EF this low.
You're right to avoid fosphenytoin on cardiac grounds — I wouldn't push back on that. But I'd also flag valproate specifically, separately from the equivalence question — valproate itself carries a real, if not fully understood, association with hyponatremia, and giving it to a patient who's already at a sodium of 121 risks compounding the exact abnormality that may have caused this seizure in the first place.
Focusing the safety argument only on his heart risks missing that his sodium is the more acute, more immediately dangerous number in the room right now — a drug that could push it lower is its own real hazard, independent of anything to do with his cardiomyopathy.
Both of those point the same direction, and levetiracetam avoids both problems at once — no meaningful cardiovascular loading effect for his EF, and no known clinically significant hyponatremia risk to compound his sodium of 121. Given ESETT's own equivalence finding, there's no efficacy cost to choosing the option that also happens to avoid two separate, real hazards specific to him.
His sodium correction should proceed carefully and separately — too-rapid correction carries its own real risk — but that's a parallel track, not a reason to delay starting the second-line seizure agent he needs right now.
Agreed: levetiracetam given as the second-line agent, chosen specifically for his cardiac and sodium profile given ESETT's own equivalence finding removed any efficacy reason to prefer either alternative. Careful, monitored sodium correction started in parallel.
Not agreed: whether his sodium of 121, rather than an unrelated structural or vascular process, is genuinely sufficient on its own to explain a first seizure at 61, or whether further workup (imaging, LP if indicated) should proceed regardless of how quickly the seizure resolves. Left as an open diagnostic question for the admitting team.